-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the official website of the State Food and Drug Administration showed that Jiangsu Hengrui Pharmaceutical's nimodipine oral liquid entered the administrative approval stage as a 3-type imitation, and is expected to win the first domestic imitation
.
According to data from Minet.
com, the sales of nimodipine in China's public medical institutions will exceed 700 million yuan in 2020.
In the first half of 2021, there will be a slight year-on-year decline.
Bayer has the largest market share
.
The data show that nimodipine is used for the improvement of blood circulation in the recovery period of acute cerebrovascular disease, the protection of ischemic neurons and the treatment of vascular dementia
.
Terminal nimodipine sales in China's public medical institutions in recent years (unit: 100 million yuan) Source: Terminal competition in China's public medical institutions Nimodipine Oral Liquid is one of the first varieties to be encouraged to develop and apply for the Children's Drug List
.
According to data from Minet.
com, in 2020, the sales of terminal nimodipine in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 700 million yuan, and the first half of 2021 fell slightly year-on-year.
, Bayer has the largest market share
.
Source: MED2.
0 China Drug Evaluation Database of Minet.
com There are injections, capsules, and tablets of nimodipine in China.
Among them, injections account for the largest market share, and there are no companies approved for oral liquids
.
A few days ago, Jiangsu Hengrui Medicine's nimodipine oral solution entered the administrative approval stage as a 3-type imitation, and is expected to win the first domestic imitation
.
In addition, Guangdong Jincheng Jinsu Pharmaceutical | Zhejiang Kangenbei Pharmaceutical is under review and approval as a 3-type generic
.
Source: State Food and Drug Administration official website, Minet database
.
According to data from Minet.
com, the sales of nimodipine in China's public medical institutions will exceed 700 million yuan in 2020.
In the first half of 2021, there will be a slight year-on-year decline.
Bayer has the largest market share
.
The data show that nimodipine is used for the improvement of blood circulation in the recovery period of acute cerebrovascular disease, the protection of ischemic neurons and the treatment of vascular dementia
.
Terminal nimodipine sales in China's public medical institutions in recent years (unit: 100 million yuan) Source: Terminal competition in China's public medical institutions Nimodipine Oral Liquid is one of the first varieties to be encouraged to develop and apply for the Children's Drug List
.
According to data from Minet.
com, in 2020, the sales of terminal nimodipine in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 700 million yuan, and the first half of 2021 fell slightly year-on-year.
, Bayer has the largest market share
.
Source: MED2.
0 China Drug Evaluation Database of Minet.
com There are injections, capsules, and tablets of nimodipine in China.
Among them, injections account for the largest market share, and there are no companies approved for oral liquids
.
A few days ago, Jiangsu Hengrui Medicine's nimodipine oral solution entered the administrative approval stage as a 3-type imitation, and is expected to win the first domestic imitation
.
In addition, Guangdong Jincheng Jinsu Pharmaceutical | Zhejiang Kangenbei Pharmaceutical is under review and approval as a 3-type generic
.
Source: State Food and Drug Administration official website, Minet database
![9-[3-Chloro-5-(phenanthren-9-yl)phenyl]phenanthrene / 1369431-34-4](https://file.echemi.com/fileManage/upload/goodpicture/20241028/9-3-chloro-5-phenanthren-9-ylphenylphenanthrene-1369431-34-4_b20241028151130118.jpg)
